Microrna diagnostic assay for chronic kidney disease
AssigneeMI:RNA Ltd.
InventorsEve HANKS, Robert COULTOUS
Life of this patent
Estimating the term…
Abstract
A method for differentially assessing and diagnosing a diseased state of chronic kidney disease (CKD) in a subject, comprising the steps of: obtaining a sample from the subject; determining a level of expression of each of a plurality of miRNA molecules within the sample; comparing the level of expression of each miRNA molecule with at least one pre-determined reference level characteristic of a non-diseased subject for each one of the plurality of the miRNA molecules of step, where a deviation of the level of expression of miRNA molecules in comparison with the at least one reference level allows for the diagnosis and/or prognosis of CKD.
Claims20
A method for differentially assessing and diagnosing a diseased state of chronic kidney disease (CKD) in a subject, comprising the steps of:
- (a) obtaining a sample from the subject;
- (b) isolating miRNA molecules within a sample from a subject;
- (c) amplifying the cDNA molecules to a detectable concentration;
- (d) probing for the cDNA molecules complimentary to the desired miRNA markers;
- (e) determining a level of expression of the miRNA molecules within a sample from a subject by the level of cDNA molecules probed for the desired miRNA markers;
- and
- (f) using one or more Artificial Intelligence (AI) model to predict the disease condition of the subject;
- wherein the one or more AI model compares the level of expression of each cDNA molecule with at least one pre-determined reference level cDNA molecule characteristic of a non-diseased subject wherein a deviation of the level of expression of said cDNA molecule in comparison with the at least one reference level cDNA molecule allows for the diagnosis and/or prognosis of CKD.
A method of selecting a panel for use in disease diagnosis comprising the steps of:
- (a) selecting a group of miRNA molecules the differential expression of which may be associated with a disease condition;
- (b) predicting the disease condition based on a deviation of the level of expression of said miRNA molecules from step (a) and (b);
- and
- (c) reducing the number of miRNAs in the panel to a minimum number to provide a panel of miRNAs that still produces a result;
- wherein the disease is CKD.
Dependencies are inferred from the claim text.